Company Description
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States.
The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and OMNI EDGE, an implant-free and minimally invasive glaucoma surgery technology.
The company also provides SION, a bladeless and manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork; and TearCare system, a proprietary, interventional, dry eye device designed to melt and facilitate the comprehensive removal of meibomian gland obstructions and restore gland functionality and healthy oil production for adult patients with evaporative dry eye disease due to meibomian gland disease when used in conjunction with manual expression of the meibomian glands for ophthalmologists and optometrists.
It serves hospitals, medical centers, and eyecare professionals through sales representatives and distributors.
The company was incorporated in 2010 and is headquartered in Menlo Park, California.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jul 15, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 186 |
| CEO | Paul Badawi |
Contact Details
Address: 4040 Campbell Avenue, Suite 100 Menlo Park, California 94025 United States | |
| Phone | 877 266 1144 |
| Website | sightsciences.com |
Stock Details
| Ticker Symbol | SGHT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $24.00 |
| CIK Code | 1531177 |
| CUSIP Number | 82657M105 |
| ISIN Number | US82657M1053 |
| Employer ID | 80-0625749 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Paul Badawi | Co-Founder, President, Chief Executive Officer and Director |
| Dr. David Badawi M.D. | Co-Founder, Chief Technology Officer and Director |
| Alison Perry Bauerlein | Chief Operating Officer |
| Jeremy B. Hayden J.D. | Chief Legal Officer and Corporate Secretary |
| James Rodberg | Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Treasurer |
| Steve R. Tamayo Jr. | Vice President and Chief Ethics and Compliance Officer |
| Brenton Taylor | Executive Vice President of Operations and Research & Development |
| Mark Papini | Senior Vice President of Interventional Glaucoma |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 4, 2026 | 10-K | Annual Report |
| Mar 4, 2026 | 8-K | Current Report |
| Feb 4, 2026 | SCHEDULE 13G/A | Filing |
| Feb 3, 2026 | 8-K | Current Report |
| Jan 21, 2026 | SCHEDULE 13G | Filing |
| Jan 16, 2026 | 144 | Filing |
| Jan 16, 2026 | 144 | Filing |
| Jan 16, 2026 | 144 | Filing |
| Jan 16, 2026 | 144 | Filing |
| Jan 16, 2026 | 144 | Filing |